This inventor holds 2 USPTO granted patents, plus 1 CIPO patent. Top assignee: Chiesi Farmaceutici S.p.a.. Active years: 2023-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023-2025
Title: Akif Emre Tureli: Innovator in Pharmaceutical Compositions
Introduction
Akif Emre Tureli is a notable inventor based in Saarlouis, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compositions that enhance drug stability and efficacy. With a total of 2 patents to his name, Tureli is recognized for his work in creating advanced pharmaceutical formulations.
Latest Patents
Tureli's latest patents include a groundbreaking pharmaceutical composition comprising clevidipine in a sterile, ready-to-use, physically stable, aqueous dispersion of nanoparticles. This formulation stabilizes clevidipine against the formation of impurities and is suitable for parenteral administration. His work in this area demonstrates a commitment to improving drug delivery systems and patient outcomes.
Career Highlights
Throughout his career, Tureli has been associated with Chiesi Farmaceutici S.p.a., where he has contributed to various research and development projects. His expertise in pharmaceutical sciences has positioned him as a valuable asset in the industry, driving innovation and enhancing therapeutic options.
Collaborations
Tureli has collaborated with several professionals in his field, including Rajeshwar Motheram and Monika Kanter. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in pharmaceutical technology.
Conclusion
Akif Emre Tureli's contributions to the pharmaceutical industry through his innovative patents and collaborations highlight his role as a key inventor in the field. His work continues to influence the development of effective and stable drug formulations, ultimately benefiting patients worldwide.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
